OncoZenge AB (publ) (”OncoZenge” or “the Company”) announces that the Company’s board member and Chief Medical Officer Dr. Chris Nowak, will present the study design for the planned registrational Phase 3 study of BupiZenge™ at the Multinational Association of Supportive Care in Cancer (MASCC) / International Society of Oral Oncology (ISOO) Annual Meeting 2025 in Seattle, Washington, USA. The study aims to compare BupiZenge™ with the current standard of care for treating pain caused by oral mucositis in cancer patients.
The oral presentation will take place within the Cancer Pain section on Saturday, June 28, 2025, at 11:35 AM local time. The presentation, titled “Confirmatory Phase 3 Trial of Lozenge-Formulated Bupivacaine (BupiZenge) for Treatment of Oral Mucositis Pain: Design and Rationale,” will be available as an e-poster online on the Company’s website at http://www.oncozenge.se/Downloads/.
Co-authors of the presentation are Dr. Pooja Nandwani (Sterling Hospital, Ahmedabad, India), Associate Professor Paolo Bossi (Humanitas University, Milan, Italy), and Professor Stephen T. Sonis (Harvard School of Dental Medicine, Boston, MA, USA). All are members of OncoZenge’s Scientific Advisory Board.
The MASCC/ISOO Annual Meeting (https://mascc.org/annualmeeting2025/) is the world’s leading interdisciplinary conference on supportive cancer care.
“Presenting our Phase 3 study at MASCC/ISOO is a great honor and an important milestone for OncoZenge. The conference provides an incredible opportunity to engage directly with clinicians, opinion leaders, and patients—those most impacted by new treatment options in practice,” says Dr. Chris Nowak, CMO of OncoZenge.
BupiZenge™ – Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se
Certified Adviser
OncoZenge’s Certified Adviser is Redeye AB.
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About this release
The information in this release was submitted for publication, through the agency of the contact persons set out above, at 14:00 CEST on June 25, 2025.
About OncoZenge
OncoZenge is dedicated to developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options fall short, often due to insufficient pain relief or significant side effects. BupiZenge™ is a novel oral lozenge formulation of bupivacaine, a local anesthetic with decades of clinical experience. The lead indication for BupiZenge™ is oral pain caused by oral mucositis, an inflammatory condition affecting millions of cancer patients. Oral mucositis leads to severe physical and psychological distress, representing a significant unmet medical need for an effective, opioid-sparing treatment. In Phase 2 trials, BupiZenge™ demonstrated substantially better pain relief compared to the standard of care.
OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.